{
  "run_id": "RUN_20260204_132700_1fed028ce5fb",
  "timestamp": "2026-02-04T16:26:08.747969",
  "document": "06_41927_2025_Article_585.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/06_41927_2025_Article_585.pdf",
  "total_candidates": 572,
  "total_validated": 30,
  "total_rejected": 0,
  "total_ambiguous": 0,
  "heuristics_counters": {
    "recovered_by_stats_whitelist": 0,
    "recovered_by_country_code": 0,
    "recovered_by_hyphen": 0,
    "recovered_by_direct_search": 0,
    "recovered_by_llm_sf_only": 3,
    "blacklisted_fp_count": 19,
    "common_word_rejected": 16,
    "context_rejected": 0,
    "form_filter_rejected": 42,
    "trial_id_excluded": 0
  },
  "abbreviations": [
    {
      "short_form": "GPA",
      "long_form": "Granulomatosis with polyangiitis",
      "confidence": 1.0,
      "field_type": "DEFINITION_PAIR",
      "page": 1,
      "context_text": "Abstract Background Granulomatosis with polyangiitis (GPA) is a rare form of antineutrophil cytoplasmic antibody (ANCA)- associated vasculitis that can involve multiple organ systems, including the gastrointestinal (Gl) tract. Although Gl manifestations are relatively uncommon, they may be associated with serious complications and adverse outcomes. This study aimed to assess the frequency and types of Gl involvement in patients with GPA and to examine th",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "ANCA",
      "long_form": "antineutrophil cytoplasmic antibody",
      "confidence": 0.95,
      "field_type": "DEFINITION_PAIR",
      "page": 1,
      "context_text": "Abstract Background Granulomatosis with polyangiitis (GPA) is a rare form of antineutrophil cytoplasmic antibody (ANCA)- associated vasculitis that can involve multiple organ systems, including the gastrointestinal (Gl) tract. Although Gl manifestations are relatively uncommon, they may be associated with serious complications and adverse outcomes. This study aimed to assess the frequency and types of Gl involvement in patients with GPA and to examine their relationship with disease severity, prognosis, and treatm",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "Gl",
      "long_form": "gastrointestinal",
      "confidence": 1.0,
      "field_type": "DEFINITION_PAIR",
      "page": 1,
      "context_text": "Abstract Background Granulomatosis with polyangiitis (GPA) is a rare form of antineutrophil cytoplasmic antibody (ANCA)- associated vasculitis that can involve multiple organ systems, including the gastrointestinal (Gl) tract. Although Gl manifestations are relatively uncommon, they may be associated with serious complications and adverse outcomes. This study aimed to assess the frequency and types of Gl involvement in patients with GPA and to examine their relationship with disease severity, prognosis, and treatment response.",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "BVAS",
      "long_form": "Birmingham Vasculitis Activity Score",
      "confidence": 1.0,
      "field_type": "DEFINITION_PAIR",
      "page": 1,
      "context_text": "involvement in patients with GPA and to examine their relationship with disease severity, prognosis, and treatment response. Methods In this retrospective cohort study, clinical records of 220 patients with a confirmed diagnosis of GPA who were referred to Amir Alam Hospital between 2013 and 2021 were reviewed. Data on demographic characteristics, Gl symptoms, Birmingham Vasculitis Activity Score (BVAS), therapeutic response, relapse rates, and mortality were collected and analyzed.",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "BVAS-WG",
      "long_form": "Birmingham Vasculitis Activity Score for Wegener's Granulomatosis",
      "confidence": 1.0,
      "field_type": "DEFINITION_PAIR",
      "page": 3,
      "context_text": "ant. Hazard ratios will be calculated to compare relapse and mortality rates between patients with and without gastrointestinal involvement. Demographics: gender, age at diagnosis, time from symptom onset to diagnosis, and follow-up duration. Clinical features: organ involvement and symptoms at presentation, assessed using the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS-WG). Gastrointestinal symptoms, including elevated liver enzymes (AST, ALT >79 IU/L; ALP > 306 IU/L), GI bleeding, diarrhea, nausea, vomiting, mesenteric ischemia, ascites, pancreatitis, hepatomegaly, hepatitis, and abdominal pain, will be documented. Treatment regimens: types, doses, and duration of induction therapies (cyclophosphamide,",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "GI",
      "long_form": "gastrointestinal",
      "confidence": 1.0,
      "field_type": "DEFINITION_PAIR",
      "page": 4,
      "context_text": "of enrollment was 50.08 + 16.26 years (range: 13-80), and the mean age at diagnosis was 44,48 +15.93 years (range: 16-80). Furthermore, most Out of the 220 patients, 18 (8.2%) exhibited gastroin-testinal (GI) involvement during follow-up before exact",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "Li",
      "long_form": "liver",
      "confidence": 1.0,
      "field_type": "DEFINITION_PAIR",
      "page": 5,
      "context_text": "ENT: ear, nose and throat, L: lung, K: kidney, P: pancreas, C: nervous system, M: mucosa, J: joint, S: skin, Li: liver, HF: heart failure, Cyc: cyclophosphamide, Aza: azathioprine, Pulse: pulse methylprednisolone, RTX: rituximab, PD: prednisolone",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "Cyc",
      "long_form": "cyclophosphamide",
      "confidence": 1.0,
      "field_type": "DEFINITION_PAIR",
      "page": 5,
      "context_text": "ENT: ear, nose and throat, L: lung, K: kidney, P: pancreas, C: nervous system, M: mucosa, J: joint, S: skin, Li: liver, HF: heart failure, Cyc: cyclophosphamide, Aza: azathioprine, Pulse: pulse methylprednisolone, RTX: rituximab, PD: prednisolone",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "Aza",
      "long_form": "azathioprine",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 5,
      "context_text": "ENT: ear, nose and throat, L: lung, K: kidney, P: pancreas, C: nervous system, M: mucosa, J: joint, S: skin, Li: liver, HF: heart failure, Cyc: cyclophosphamide, Aza: azathioprine, Pulse: pulse methylprednisolone, RTX: rituximab, PD: prednisolone",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "Pulse",
      "long_form": "pulse methylprednisolone",
      "confidence": 1.0,
      "field_type": "DEFINITION_PAIR",
      "page": 5,
      "context_text": "ENT: ear, nose and throat, L: lung, K: kidney, P: pancreas, C: nervous system, M: mucosa, J: joint, S: skin, Li: liver, HF: heart failure, Cyc: cyclophosphamide, Aza: azathioprine, Pulse: pulse methylprednisolone, RTX: rituximab, PD: prednisolone",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "FVSG",
      "long_form": "French Vasculitis Study Group",
      "confidence": 0.95,
      "field_type": "DEFINITION_PAIR",
      "page": 8,
      "context_text": "in systemic vasculitis is not a novel finding; it has been a cornerstone of risk stratification for decades, most notably through its inclusion in the Five-Factor Score (FFS). Initially developed for polyarteritis nodosa (PAN), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, then CSS), the FFS was revised and validated by the French Vasculi-tis Study Group (FVSG) in 2009 to include GPA. In this large cohort of 1,108 patients, the revised FFS identified four factors including age >65 years, cardiac involvement, renal insufficiency (creatinine > 150 mol/L), and GI involvement that were each independently associated with a higher 5-year mortality and accorded + 1 point. Our data strongly support this long-standing observation, confirming that GI involvement",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "FFS",
      "long_form": "FFS (clinical trial)",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 8,
      "context_text": "The prognostic significance of GI involvement in systemic vasculitis is not a novel finding; it has been a cornerstone of risk stratification for decades, most notably through its inclusion in the Five-Factor Score (FFS). Initially developed for polyarteritis nodosa (PAN), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, then CSS), the FFS was revised and validated by the French Vasculi-tis Study Group (FVSG) in 2009 to include GPA. In this large cohort of 1,108 patients, th",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "MPA",
      "long_form": "microscopic polyangiitis",
      "confidence": 1.0,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "Based on EMA and CHCC 2012 the patient in four ways diagnosed GPA (Fig. 1): (1) Based on ACR 1990 diagnosed GPA, (2) Biopsy proven tissue sample for GPA, (3) Tissue sample confirmed MPA but clinical sign and symptoms of GPA, (4) ANCA positive and clinical features of GPA without tissue sample.",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "CHCC",
      "long_form": "Chapel Hill Consensus Conference",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "Based on EMA and CHCC 2012 the patient in four ways diagnosed GPA (Fig. 1): (1) Based on ACR 1990 diagnosed GPA, (2) Biopsy proven tissue sample for GPA, (3) Tissue sample confirmed MPA but clinical sign and symptoms of GPA, (4) ANCA positive and clinical features of GPA without tissue sample.",
      "lexicon_source": "meta-inventory",
      "lexicon_ids": null
    },
    {
      "short_form": "PAN",
      "long_form": "polyarteritis nodosa",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "Exclusion criteria’s: patients meet criteria for EGPA, patient has small vessels features, ANCA + but no GPA features, biopsy or imaging evidence consistent with PAN {12].",
      "lexicon_source": "2025_mondo_diseases.json",
      "lexicon_ids": [
        {
          "source": "MONDO",
          "id": "MONDO_0019170"
        },
        {
          "source": "DOID",
          "id": "DOID:9810"
        },
        {
          "source": "GARD",
          "id": "GARD:7360"
        },
        {
          "source": "ICD10CM",
          "id": "ICD10CM:M30.0"
        },
        {
          "source": "ICD9",
          "id": "ICD9:446.0"
        },
        {
          "source": "MEDGEN",
          "id": "MEDGEN:14681"
        },
        {
          "source": "MESH",
          "id": "MESH:D010488"
        },
        {
          "source": "MedDRA",
          "id": "MedDRA:10036024"
        },
        {
          "source": "NANDO",
          "id": "NANDO:1200261"
        },
        {
          "source": "NANDO",
          "id": "NANDO:2200425"
        },
        {
          "source": "NCIT",
          "id": "NCIT:C26847"
        },
        {
          "source": "NORD",
          "id": "NORD:1588"
        },
        {
          "source": "Orphanet",
          "id": "Orphanet:767"
        },
        {
          "source": "SCTID",
          "id": "SCTID:155441006"
        },
        {
          "source": "UMLS",
          "id": "UMLS:C0031036"
        },
        {
          "source": "icd11.foundation",
          "id": "icd11.foundation:1419332129"
        }
      ]
    },
    {
      "short_form": "EGPA",
      "long_form": "eosinophilic granulomatosis with polyangiitis",
      "confidence": 1.0,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "Exclusion criteria’s: patients meet criteria for EGPA, patient has small vessels features, ANCA + but no GPA features, biopsy or imaging evidence consistent with PAN {12].",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "MPO",
      "long_form": "myeloperoxidase",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 3,
      "context_text": "Patients with clinical diagnosis of vasculitis Yes ™e EGPA <— — Meets ACR criteria for EGPA Ny Yes GPA Meets ACR criteria for GPA Yes GPA g¢_ Biopsy consistent with GPA (CHCC) Yes GPA ¢—— Yes GPA gq Yes MPA Yes a Biopsy consistent with MPA (CHCC) + clinical GPA features Na ANCA positive (PR3/MPO) + clinical GPA features, no biopsy a <¢— Clinical + biopsy evidence of small vessels vasculitis no GPA features Na MPA <— _ ANCA positive (PR3/MPO) + Renal vasculitis no GPA features Yes ™a PAN —— Biopsy/Angiographic evidence consistent with PAN (CHCC) ™a",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "PR3",
      "long_form": "proteinase 3",
      "confidence": 0.95,
      "field_type": "DEFINITION_PAIR",
      "page": 3,
      "context_text": "Patients with clinical diagnosis of vasculitis Yes ™e EGPA <— — Meets ACR criteria for EGPA Ny Yes GPA Meets ACR criteria for GPA Yes GPA g¢_ Biopsy consistent with GPA (CHCC) Yes GPA ¢—— Yes GPA gq Yes MPA Yes a Biopsy consistent with MPA (CHCC) + clinical GPA features Na ANCA positive (PR3/MPO) + clinical GPA features, no biopsy a <¢— Clinical + biopsy evidence of small vessels vasculitis no GPA features Na MPA <— _ ANCA positive (PR3/MPO) + Renal vasculitis no GPA features Yes ™a PAN —— Biopsy/Angiographic evidence consistent with PAN (CHCC) ™a",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "WG",
      "long_form": "Wegener's granulomatosis",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 3,
      "context_text": "methylprednisolone) and maintenance therapies (prednisolone, azathioprine, methotrexate, mycophenolate mofetil). Treatment response: assessed using BVAS-WG scores. Complete remission is defined as a BVAS-WG score of zero after treatment, partial remission as a>50% reduction in BVAS-WG, and relapse as any increase in BVAS-WG. Prognostic outcomes: relapse and mortality rates.",
      "lexicon_source": "meta-inventory",
      "lexicon_ids": null
    },
    {
      "short_form": "ALP",
      "long_form": "alkaline phosphatase",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 3,
      "context_text": "from symptom onset to diagnosis, and follow-up duration. Clinical features: organ involvement and symptoms at presentation, assessed using the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS-WG). Gastrointestinal symptoms, including elevated liver enzymes (AST, ALT >79 IU/L; ALP > 306 IU/L), GI bleeding, diarrhea, nausea, vomiting, mesenteric ischemia, ascites, pancreatitis, hepatomegaly, hepatitis, and abdominal pain, will be documented. Treatment regimens: types, doses, and duration of induction therapies (cyclophosphamide,",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "ALT",
      "long_form": "alanine aminotransferase",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 3,
      "context_text": "agnosis, time from symptom onset to diagnosis, and follow-up duration. Clinical features: organ involvement and symptoms at presentation, assessed using the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS-WG). Gastrointestinal symptoms, including elevated liver enzymes (AST, ALT >79 IU/L; ALP > 306 IU/L), GI bleeding, diarrhea, nausea, vomiting, mesenteric ischemia, ascites, pancreatitis, hepatomegaly, hepatitis, and abdominal pain, will be documented. Treatment regimens: types, doses, and duration of induction therapies (cyclophosphamide,",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "AST",
      "long_form": "aspartate aminotransferase",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 3,
      "context_text": "at diagnosis, time from symptom onset to diagnosis, and follow-up duration. Clinical features: organ involvement and symptoms at presentation, assessed using the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS-WG). Gastrointestinal symptoms, including elevated liver enzymes (AST, ALT >79 IU/L; ALP > 306 IU/L), GI bleeding, diarrhea, nausea, vomiting, mesenteric ischemia, ascites, pancreatitis, hepatomegaly, hepatitis, and abdominal pain, will be documented. Treatment regimens: types, doses, and duration of induction therapies (cyclophosphamide,",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "ENT",
      "long_form": "Ear, nose and throat",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 5,
      "context_text": "Patientno. Age LagofDx(months) Serology Organ involvment at GPA diagnosis First BVAS InductionTx MaintenanceTx Prognosis 65 3-ENT, LK, PM 391-Li, ENT. 38 0 PR3 Li, ENT, LK, eye, HF 63 4 PR3 ENT, K;S, Li 62 3 PR3 Li, GENT, L 68 2 PR3 ENT, Li 51 0-Li, ENT, LK, eye, S 56 2 PR3 ENT, Keye, C,Li 54. 6 PR3 ENT, LK, Li 28 4 PR3 ENT, LK, Li 68 0 PR3 ENT, L.Li, JM 69 0 PR3 ENT, Li, MJ 58 2 PR3 ENT, K,C, eye, Li 51 0 PR3 ENT, K,C, eye,",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "HF",
      "long_form": "heart failure",
      "confidence": 0.7,
      "field_type": "DEFINITION_PAIR",
      "page": 5,
      "context_text": "Patientno. Age LagofDx(months) Serology Organ involvment at GPA diagnosis First BVAS InductionTx MaintenanceTx Prognosis 65 3-ENT, LK, PM 391-Li, ENT. 38 0 PR3 Li, ENT, LK, eye, HF 63 4 PR3 ENT, K;S, Li 62 3 PR3 Li, GENT, L 68 2 PR3 ENT, Li 51 0-Li, ENT, LK, eye, S 56 2 PR3 ENT, Keye, C,Li 54. 6 PR3 ENT, LK, Li 28 4 PR3 ENT, LK, Li 68 0 PR3 ENT, L.Li, JM 69 0 PR3 ENT, Li, MJ 58 2 PR3 ENT, K,C, eye, Li 51 0 PR3 ENT, K,C, eye, MLi 50 4-ENT, Li 52 3 PR3 ENT, LG, Li 39 0 PR3 ENT,",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "MTX",
      "long_form": "methotrexate",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 5,
      "context_text": "4-ENT, Li 52 3 PR3 ENT, LG, Li 39 0 PR3 ENT, KL, Geye, HF, Li 40 2 PR3 ENT, Li 34 Cyc PD, RTX, Cyc D 13 Cyc+Pulse = PD5,Aza L 34 Cyc+Pulse = PD5,Aza D 26 Cyc+Pulse = PD7.5 D 19 Cyc + Pulse PDS50,Aza L 9 Cyc PD2.5 L 32 Cyc + Pulse PD, RTX, Cyc D 28 Cyc+Pulse = PD60 D 17 Cyc+Pulse — Celcept, PD60 L 6 MTX MTX, PD30 D 18 Aza+pulse = PDS L 15 Aza+pulse = RTX L 30 Cyc+Pulse = PD30 D 35 Cyc+Pulse = PD45,Cyc D 6 MTX PD60,Cyc D 19 Cyc + Pulse PD60,Aza L 37 Cyc+Pulse = PDS D 9 Aza RTX L",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "RTX",
      "long_form": "rituximab",
      "confidence": 1.0,
      "field_type": "DEFINITION_PAIR",
      "page": 5,
      "context_text": "2 PR3 ENT, Li 51 0-Li, ENT, LK, eye, S 56 2 PR3 ENT, Keye, C,Li 54. 6 PR3 ENT, LK, Li 28 4 PR3 ENT, LK, Li 68 0 PR3 ENT, L.Li, JM 69 0 PR3 ENT, Li, MJ 58 2 PR3 ENT, K,C, eye, Li 51 0 PR3 ENT, K,C, eye, MLi 50 4-ENT, Li 52 3 PR3 ENT, LG, Li 39 0 PR3 ENT, KL, Geye, HF, Li 40 2 PR3 ENT, Li 34 Cyc PD, RTX, Cyc D 13 Cyc+Pulse = PD5,Aza L 34 Cyc+Pulse = PD5,Aza D 26 Cyc+Pulse = PD7.5 D 19 Cyc + Pulse PDS50,Aza L 9 Cyc PD2.5 L 32 Cyc + Pulse PD, RTX, Cyc D 28 Cyc+Pulse = PD60 D 17 Cyc+Pulse — Celcept, PD60 L 6 MTX MTX, PD30 D 18 Aza+pulse = PDS L 15 Aza+pulse = RTX L 30 Cyc+Pulse = PD30 D 35 Cyc+Pulse",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "ANCOVA",
      "long_form": "Analysis Of Covariance",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 5,
      "context_text": "ith GI manifestations compared to those without (21.0 + 10.13 vs. 15.8 + 7.43; p =0.004). Similarly, after follow-up time with median of 19 months, patients with GI symptoms continued to exhibit higher disease activity (8.47+9.24 vs. 4.43 +7.72; p=0.042). However, when adjusted for covariates using ANCOVA, the difference in final BVAS scores between the two groups was not statistically significant (adjusted mean 0.66+1.11 vs. 4.66 + 0.52; p= 0.266) (Table 3).",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "AAVs",
      "long_form": "ANCA-associated vasculitides",
      "confidence": 0.85,
      "field_type": "DEFINITION_PAIR",
      "page": 1,
      "context_text": "une vasculitis classified under antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) [1]. It mostly affects small to medium sized vessels and may result in multiorgan dysfunction and ",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "ACR",
      "long_form": "American College of Rheumatology",
      "confidence": 0.85,
      "field_type": "DEFINITION_PAIR",
      "page": 1,
      "context_text": "volving Iranian patients diagnosed with GPA according to the 1990 American College of Rheumatology (ACR) criteria and the European Medicines Agency (EMA) algorithm. The study includes all patients aged 1",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "MRI",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": "is, ANCA positive, confirm vasculitis or granuloma by other diagnostic modality like angiography or MRI [11]. Based on EMA and CHCC 2012 the patient in four ways diagnosed GPA (Fig. 1): (1) Based on ACR ",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    }
  ],
  "diseases": [
    {
      "name": "Anti-neutrophil cytoplasmic antibody-associated vasculitis",
      "matched_text": "ANCA-Associated vasculitis",
      "abbreviation": "AAV",
      "confidence": 1.0,
      "is_rare": true,
      "icd10": null,
      "orpha": "ORPHA:156152"
    },
    {
      "name": "Eosinophilic granulomatosis with polyangiitis",
      "matched_text": "EGPA",
      "abbreviation": "EGPA",
      "confidence": 0.97,
      "is_rare": true,
      "icd10": "M30.1",
      "orpha": "ORPHA:183"
    },
    {
      "name": "central nervous system vasculitis",
      "matched_text": "central nervous system vasculitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "Granulomatosis with polyangiitis",
      "matched_text": "granulomatosis with polyangiitis",
      "abbreviation": "GPA",
      "confidence": 1.0,
      "is_rare": true,
      "icd10": "M31.3",
      "orpha": "ORPHA:900"
    },
    {
      "name": "Well-differentiated liposarcoma",
      "matched_text": "ALT",
      "abbreviation": "ALT",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "C49.9",
      "orpha": "ORPHA:99971"
    },
    {
      "name": "Epilepsy with eyelid myoclonia",
      "matched_text": "EMA",
      "abbreviation": "EMA",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "G40.3",
      "orpha": "ORPHA:139431"
    },
    {
      "name": "Multiple epiphyseal dysplasia",
      "matched_text": "Med",
      "abbreviation": "MED",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": null,
      "orpha": "ORPHA:251"
    },
    {
      "name": "Marburg hemorrhagic fever",
      "matched_text": "MHF",
      "abbreviation": "MHF",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "A98.3",
      "orpha": "ORPHA:99826"
    },
    {
      "name": "Microscopic polyangiitis",
      "matched_text": "MPA",
      "abbreviation": "MPA",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "M31.7",
      "orpha": "ORPHA:727"
    },
    {
      "name": "microscopic polyangiitis",
      "matched_text": "microscopic polyangiitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:M31.7",
      "orpha": "Orphanet:727"
    },
    {
      "name": "Femoral-facial syndrome",
      "matched_text": "FFS",
      "abbreviation": "FFS",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "Q87.8",
      "orpha": "ORPHA:1988"
    },
    {
      "name": "intestinal perforation",
      "matched_text": "intestinal perforation",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "autoimmune vasculitis",
      "matched_text": "autoimmune vasculitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "Polyarteritis nodosa",
      "matched_text": "PAN",
      "abbreviation": "PAN",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "M30.0",
      "orpha": "ORPHA:767"
    },
    {
      "name": "polyarteritis nodosa",
      "matched_text": "polyarteritis nodosa",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:M30.0",
      "orpha": "Orphanet:767"
    },
    {
      "name": "rheumatoid arthritis",
      "matched_text": "rheumatoid arthritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:284130"
    },
    {
      "name": "systemic vasculitis",
      "matched_text": "systemic vasculitis",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "renal insufficiency",
      "matched_text": "renal insufficiency",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "facial nerve palsy",
      "matched_text": "facial nerve palsy",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:G51.0",
      "orpha": "Orphanet:2810"
    },
    {
      "name": "splenic infarction",
      "matched_text": "splenic infarction",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:D73.5",
      "orpha": null
    },
    {
      "name": "Pendred syndrome",
      "matched_text": "PDS",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:705"
    },
    {
      "name": "Hydrops fetalis",
      "matched_text": "HF",
      "abbreviation": "HF",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "P83.2",
      "orpha": "ORPHA:1041"
    },
    {
      "name": "HELLP syndrome",
      "matched_text": "elevated liver enzymes",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": true,
      "icd10": null,
      "orpha": "ORPHA:244242"
    },
    {
      "name": "heart failure",
      "matched_text": "heart failure",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare": false,
      "icd10": "ICD10CM:I50",
      "orpha": null
    },
    {
      "name": "pancreatitis",
      "matched_text": "pancreatitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "eosinophilia",
      "matched_text": "eosinophilia",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:D72.11",
      "orpha": "Orphanet:168956"
    },
    {
      "name": "GI bleeding",
      "matched_text": "GI bleeding",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "proteinuria",
      "matched_text": "proteinuria",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:R80",
      "orpha": null
    },
    {
      "name": "Pyomyositis",
      "matched_text": "PM",
      "abbreviation": "PM",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "M60.0",
      "orpha": "ORPHA:764"
    },
    {
      "name": "malignancy",
      "matched_text": "malignancy",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "infectious",
      "matched_text": "infectious",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:A00-B99",
      "orpha": null
    },
    {
      "name": "Hepatitis",
      "matched_text": "hepatitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "gastritis",
      "matched_text": "gastritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "arthritis",
      "matched_text": "arthritis",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "scleritis",
      "matched_text": "scleritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:H15.0",
      "orpha": null
    },
    {
      "name": "ischemia",
      "matched_text": "ischemia",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "diarrhea",
      "matched_text": "diarrhea",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "colitis",
      "matched_text": "colitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "uveitis",
      "matched_text": "uveitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:98715"
    },
    {
      "name": "ulcers",
      "matched_text": "ulcers",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "asthma",
      "matched_text": "asthma",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:J45",
      "orpha": null
    },
    {
      "name": "GPA",
      "matched_text": "GPA",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:M31.3",
      "orpha": "Orphanet:900"
    },
    {
      "name": "CSS",
      "matched_text": "CSS",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:M30.1",
      "orpha": "Orphanet:183"
    },
    {
      "name": "LAM",
      "matched_text": "Lam",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:J84.81",
      "orpha": null
    }
  ],
  "drugs": [
    {
      "name": "Methylprednisolone",
      "matched_text": "methylprednisolone",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": "ACTIVE_NOT_RECRUITING"
    },
    {
      "name": "Prednisolone",
      "matched_text": "prednisolone",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": "ACTIVE_NOT_RECRUITING"
    },
    {
      "name": "Mycophenolate mofetil",
      "matched_text": "mycophenolate mofetil",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": "RECRUITING"
    },
    {
      "name": "Cyclophosphamide",
      "matched_text": "cyclophosphamide",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": "ACTIVE_NOT_RECRUITING"
    },
    {
      "name": "Methotrexate",
      "matched_text": "MTX",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": "RECRUITING"
    },
    {
      "name": "Azathioprine",
      "matched_text": "Aza",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": "ACTIVE_NOT_RECRUITING"
    },
    {
      "name": "Rituximab",
      "matched_text": "rituximab",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": "RECRUITING"
    }
  ],
  "pharma": []
}